There is a concerted effort to identify biomarkers to understand the risk of progression of diabetic eye disease, but many studies have not been performed in diverse populations, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.
There is a concerted effort to identify biomarkers to understand the risk of progression of diabetic eye disease, but many studies have not been performed in diverse populations, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.
Transcript
You recently published on the need to study circulatory biomarkers in a more diverse population. Can you explain the issue of the lack of study into the performance of biomarkers in racially and ethnically diverse populations?
There's a huge unmet need for biomarkers that may help us better understand risk of progression and worsening of diabetic eye disease in our patients. Right now, we don't have great ways to predict who may lose vision, who may develop more advanced complications, aside from our classic Early Treatment Diabetic Retinopathy Study scale, which only looks at the vascular lesions of diabetes and doesn't include the entire retina, and it doesn't at all include things like neural retinal disease or visual function or the molecular pathways that may lead to disease.
I think there's a concerted effort going on these days, and some of this is being stood up by a project known as the Mary Tyler Moore Vision Initiative. The late Mary Tyler Moore was a remarkable film and TV actress who had type 1 diabetes who served as a very strong advocate for patients with diabetes throughout her life, and she lost a lot of vision because of diabetic retinopathy. So, in her honor and her memory, her husband Robert Levine has started a project trying to create platforms to help accelerate research and development of new therapeutics and preventions in the area of diabetic retinal disease.
As part of this we also recognize that many of our studies have been performed in populations that are not as diverse as we would ideally like to see. I think in future studies, looking across racially/ethnically diverse populations is really important, because we need to understand: Do biomarkers behave the same way across populations? How do we know when we can generalize the results of one study to global populations who may have very large needs in terms of diabetic retinopathy prevention and treatment?
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been worsening. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More